Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna, and Boston Scientific Editor Note: For more information about this release, please scroll to bottom PR Newswire NEW YORK, November 6, 2013 NEW YORK, November 6, 2013 /PRNewswire/ -- Today, Analysts' Corner announced new research reports highlighting Merck & Co., Inc. (NYSE: MRK), Perrigo Company (NYSE: PRGO), Celgene Corporation (NASDAQ: CELG), Cigna Corporation (NYSE: CI), and Boston Scientific Corporation (NYSE: BSX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below. Merck & Co., Inc. Research Report On November 2, 2013, Merck & Co., Inc. (Merck) announced the presentation of interim data from the ongoing C-WORTHY Study, a Phase II clinical trial evaluating the efficacy and safety of an all-oral regimen combining once-daily MK-5172, an investigational hepatitis C virus (HCV) NS3/4A protease inhibitor, and MK-8742, an investigational HCV NS5A replication complex inhibitor, with or without twice-daily ribavirin, administered for 12 weeks to treatment-naïve, non-cirrhotic patients with HCV genotype 1a and 1b infection. According to the Company, the interim data show that the administration of MK-5172 and MK-8742 in combination is associated with sustained virologic response (lack of detectable and quantifiable HCV) 12 weeks following the end of study therapy (SVR12). Dr. Eliav Barr, Vice President, Infectious Diseases, Merck Research Laboratories, said, "These data provide further support that we can advance these candidates, which are currently in Phase IIB clinical development, into a broader evaluation in a diverse range of HCV patients." The Full Research Report on Merck & Co., Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/430d_MRK] -- Perrigo Company Research Report On November 1, 2013, Perrigo Company (Perrigo) announced that it has started a voluntary, nationwide product recall to the retail level of 18 batches of its acetaminophen infant suspension liquid, 160 mg/5 mL, sold in 2 oz. and 4 oz. bottles with syringes in a box under store brand products the Company listed on its website. The Company said that it initiated a recall because of the remote potential that a small number of packages might contain an oral dosing syringe without dose markings. The Company added that the correct syringe should have a white or yellow plunger with specific dose markings for 1.25 mL, 2.5 mL, 3.75 mL, and 5 mL. Further, Perrigo informed that if the product's syringe has these dose markings, customers can continue to use them while following labeled use instructions. Perrigo is conducting the recall with the knowledge of the US Food and Drug Administration. The Full Research Report on Perrigo Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/4168_PRGO] -- Celgene Corporation Research Report On October 30, 2013, Celgene Corporation (Celgene) announced that on November 12, 2013, the Company's management will present at the Credit Suisse Healthcare Conference in Phoenix, Arizona, at 4:30 p.m. ET. The Company added that on December 2, 2013, it will present at the Deutsche Bank BioFEST Conference in Boston, Massachusetts, at 9:00 a.m. ET. Lastly, Celgene reported that on December 8, 2013, it will present at the American Society of Hematology in New Orleans, Louisiana, at 9:30 p.m. ET. The Full Research Report on Celgene Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7f47_CELG] -- Cigna Corporation Research Report On October 31, 2013, Cigna Corporation (Cigna) announced that Cigna Medicare Advantage plans in Florida achieved five stars, the highest possible rating, from the Centers for Medicare & Medicaid Services (CMS), making the Company one of 11 five-star plans nationally and the only publicly traded Company to achieve five-star rating for its Medicare Advantage business. According to the Company, its Florida Medicare Advantage business serves more than 44,000 customers and includes Cigna-HealthSpring plan choices in Bay, Escambia and Santa Rosa counties as well as Leon Medical Centers Health Plans by Cigna-HealthSpring in Miami-Dade County, which serves customers with a high-touch experience through state-of-the-art medical centers. Cigna further reported that CMS evaluates more than 50 measures in nine categories from medical outcomes data, information from health care providers and health plans, as well as customer satisfaction surveys; among them are preventive care, managing chronic diseases and customer experience. The Full Research Report on Cigna Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/7307_CI] -- Boston Scientific Corporation Research Report On November 1, 2013, Boston Scientific Corporation (Boston Scientific) announced that it closed on its previously announced agreement to acquire Bard EP, the electrophysiology (EP) business of C.R. Bard, Inc. (Bard). According to Boston Scientific, this acquisition enables the Company to provide a broader portfolio of EP tools, including solutions for cardiac catheter ablations. Pete Sommerness, General Manager, Electrophysiology, Boston Scientific, said, "We believe that the complementary capabilities that this transaction brings, including expertise in capital equipment sales and service, will enable us to offer more complete solutions to help electrophysiologists diagnose and treat patients with cardiac arrhythmias." The Company currently expects net impact of the transaction on adjusted EPS to be immaterial in full-year 2013 and approximately accretive by $0.01 in full-year 2014, and dilutive on a GAAP basis in both years as a result of acquisition-related net charges and amortization, which will be determined subsequent to the closing of this transaction. The Full Research Report on Boston Scientific Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.analystscorner.com/r/full_research_report/5640_BSX] ---- EDITOR NOTES: 1.This is not company news. We are an independent source and our views do not reflect the companies mentioned. 2.Information in this release is fact checked and produced on a best efforts basis and reviewed by Ananya Ghosh, a CFA charterholder. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below. 3.This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public. 4.If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com. 5.For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com. 6.Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration. COMPLIANCE PROCEDURE Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be. NOT FINANCIAL ADVICE Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein. NO WARRANTY OR LIABILITY ASSUMED Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute. SOURCE Analysts' Corner Contact: CONTACT PERSON: Joe Thomas CONTACT PHONE: +1-310-496-8071 (North America)
Positive Clinical Data, Upcoming Presentations, and Completed Acquisitions - Research Report on Merck, Perrigo, Celgene, Cigna,
Press spacebar to pause and continue. Press esc to stop.